INTS vs. AVRO, CDTX, GNTA, ENTX, ALGS, LENZ, QNCX, TSBX, OKYO, and CYTH
Should you be buying Intensity Therapeutics, Inc. Common stock stock or one of its competitors? The main competitors of Intensity Therapeutics, Inc. Common stock include AVROBIO (AVRO), Cidara Therapeutics (CDTX), Genenta Science (GNTA), Entera Bio (ENTX), Aligos Therapeutics (ALGS), LENZ Therapeutics (LENZ), Quince Therapeutics (QNCX), Turnstone Biologics (TSBX), OKYO Pharma (OKYO), and Cyclo Therapeutics (CYTH). These companies are all part of the "biological products, except diagnostic" industry.
AVROBIO (NASDAQ:AVRO) and Intensity Therapeutics, Inc. Common stock (NASDAQ:INTS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, community ranking, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.
In the previous week, AVROBIO and AVROBIO both had 6 articles in the media. AVROBIO's average media sentiment score of 1.89 beat Intensity Therapeutics, Inc. Common stock's score of 0.69 indicating that Intensity Therapeutics, Inc. Common stock is being referred to more favorably in the news media.
62.6% of AVROBIO shares are owned by institutional investors. Comparatively, 3.7% of Intensity Therapeutics, Inc. Common stock shares are owned by institutional investors. 9.2% of AVROBIO shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
AVROBIO currently has a consensus target price of $2.00, indicating a potential upside of 62.60%. Intensity Therapeutics, Inc. Common stock has a consensus target price of $12.00, indicating a potential upside of 200.00%. Given AVROBIO's stronger consensus rating and higher possible upside, analysts plainly believe Intensity Therapeutics, Inc. Common stock is more favorable than AVROBIO.
AVROBIO's return on equity of 0.00% beat Intensity Therapeutics, Inc. Common stock's return on equity.
AVROBIO received 168 more outperform votes than Intensity Therapeutics, Inc. Common stock when rated by MarketBeat users. However, 100.00% of users gave Intensity Therapeutics, Inc. Common stock an outperform vote while only 66.93% of users gave AVROBIO an outperform vote.
AVROBIO has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, Intensity Therapeutics, Inc. Common stock has a beta of 4.03, meaning that its share price is 303% more volatile than the S&P 500.
Summary
Intensity Therapeutics, Inc. Common stock beats AVROBIO on 8 of the 12 factors compared between the two stocks.
Get Intensity Therapeutics, Inc. Common stock News Delivered to You Automatically
Sign up to receive the latest news and ratings for INTS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Intensity Therapeutics, Inc. Common stock Competitors List
Related Companies and Tools
